Operative Rigid Bronchoscopy treatment.The novel coronavirus (SARS-CoV-2) has distinct clinical manifestations that can vary from an asymptomatic condition to severe acute respiratory failure. Phenotypes are attributable to different pathophysiological mechanisms and require different treatment strategies. The assessment and identification of different phenotypes can guide therapy configurations such as oxygen therapy, non-invasive ventilation, airway management, and tracheal intubation. Further studies are essential to provide information on the influence of phenotypes in the decision of rehabilitation strategies. The sequelae left in the respiratory system of COVID-19 survivors and its limitations will be a challenge for rehabilitation services worldwide. Lung injuries are directly related to the phenotypes presented, and depending on the degree of these injuries, rehabilitation strategies can be targeted. We believe that differentiating patients, according to their respective phenotypes, can improve decision-making in treatment and individualized rehabilitation.Coronavirus Disease-2019 (COVID-19) is the worst worldwide pandemic with more than 12,000,000 cases and 560,000 deaths until 14th July 2020. Men were more infected by COVID-19 than women, and male subjects with underlying conditions, including diabetes, hypertension, and cardiovascular diseases developed a severe form of the affection, with increased mortality rate. Many factors can contribute to the disparity in disease outcomes, such as hormone-specific reaction and activity of X-linked genes, which modulate the innate and adaptive immune response to virus infection. Until now, only the Remdesivir was approved by FDA (Food Drug Administration) for COVID-19 treatment, although several clinical trials are ongoing worldwide also on other drugs. In this review, we analyzed published studies on several drugs (chloroquine or hydroxychloroquine, remdesivir, favipiravir, lopinavir-ritonavir in combination, tocilizumab, plasma, and immunoglobulins) with some efficacy to COVID-19 in humans, and evaluated if there were a gender analysis of the available data. In our opinion, it is essential to report data about COVID-19 disaggregated by sex, age, and race, because the knowledge of gender differences is fundamental to identify effective and customized treatments to reduce hospitalizations, admissions to intensive care units, and mortality.A worldwide outbreak of a respiratory illness, first detected in December 2019 in Wuhan city, Hubei province, China is ongoing. The disease is caused by a novel coronavirus, SARS-CoV-2 and on February 11, 2020, was officially named Coronavirus Disease 2019 (COVID-19) by the World Health Organization. Within few weeks, it has spread globally to the extent that World Health Organization declared it as a global pandemic on March 11, 2020. India's first positive case was reported on January 30th in Kerala. Before March 3rd, India had 3 cases of coronavirus in Kerala all of which were treated and discharged. On March 3rd, India's 4th case was diagnosed in the state of Rajasthan. Indian government had announced a number of preventive measures to minimize the entry and spread of coronavirus. https://www.selleckchem.com/products/nu7026.html On March 3rd, India announced the suspension of all visas issued to Italy, Iran, South Korea and Japan. India banned international flights from March 22nd. A 21-day lockdown across the country was imposed from March 26th, which later got further extended. Rigorous contact tracing and tracking of COVID patients and monitoring home quarantine helped in preventing community transmission. The aim of this work is to describe the experience with clinical and epidemiologic features, as well as with the management of COVID-19 patients in north India. This is a descriptive study of the 17 COVID-19 infected patients confirmed with polymerase chain reaction (PCR) and admitted to a tertiary care centre in India from March 11th 2020 to April 16th 2020. The present work also provides insight in to treatment provided and final outcome of the patients infected with COVID-19 in India. Laboratory investigations in COVID-19 patients in the Indian subcontinent reveal lymphopenia as predominant finding in hemogram. Patients with older age and associated comorbidities (COPD, hypertension and diabetes) seem to have greater risk for lung injury, thereby requiring oxygen support during the course of disease. Beta-alanine has become a dietary supplement widely used by athletes due to its ergogenic effect. However, there is still no consensus on the performance benefit of beta-alanine on exercise lasting longer than ten minutes. The present study aimed to evaluate the effect of beta-alanine supplementation on running performance and the expression of TauT and PAT1. This double-blind, randomized study enrolled 16 long-distance runners (37 ± 8 years) who were randomly allocated to two groups Placebo (PLA) and Beta-alanine (BA) (4.8 g·day-1) for four weeks. Maximal oxygen consumption, anthropometry, body composition, and food intake were determined. Before and after the intervention, the athletes undertook a 5,000 m running time trial. Venous blood (TauT and PAT1 expressions) and ear lobe capillary blood (lactate) collected before and after exercise. Between tests, we monitored the training variables. The results were analyzed by T-tests and an ANOVA of repeated measures, with Sidak's post hoc (p<0.05). PLA exhibited lower body fat than BA (8.7 ± 2.2 vs. 11.5 ± 2.8%, p=0.04). After supplementation, there was an increase in PAT1 expression in BA when compared to PLA (1.17 ± 0.47 vs. 0.77 ± 0.18, p=0.04). No significant differences were shown for the 5,000 m running time in PLA (PRE1128 ± 72; POST1123 ± 72s) and BA (PRE1107 ± 95; POST1093 ± 86s). Although beta-alanine supplementation increased PAT1 expression, there was no statistically significant improvement in 5,000 m running performance. However, individual responses should be considered as the BA showed a higher delta than the PLA. Although beta-alanine supplementation increased PAT1 expression, there was no statistically significant improvement in 5,000 m running performance. However, individual responses should be considered as the BA showed a higher delta than the PLA.